Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.2380
Abstract: Importance The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has single-agent activity in R/R ALL. Objective To evaluate the… read more here.
Keywords: relapsed refractory; inotuzumab; salvage; acute lymphoblastic ... See more keywords
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25757
Abstract: Urelumab, a fully human, non‐ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T‐cell and natural killer‐cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with… read more here.
Keywords: relapsed refractory; combination; patients relapsed; cell ... See more keywords
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA‐MM subgroup analysis
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26319
Abstract: die of BM failure. This similarity to MDS-Mut in clinical presentation and natural history raises the possibility that MDS-NDM cases may harbor mutations in genes not covered in standard sequencing panels, or not detected in… read more here.
Keywords: frail patients; dexamethasone frail; pomalidomide dexamethasone; plus pomalidomide ... See more keywords
Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26480
Abstract: In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D‐Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma… read more here.
Keywords: pomalidomide dexamethasone; daratumumab; health; relapsed refractory ... See more keywords
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26771
Abstract: Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there… read more here.
Keywords: myelodysplastic syndromes; relapsed refractory; venetoclax azacitidine; phase study ... See more keywords
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26866
Abstract: Patient‐reported outcomes in AL amyloidosis have not been well‐studied. We analyzed health‐related quality of life (HRQOL) and AL amyloidosis symptoms data from the phase 3 TOURMALINE‐AL1 trial (NCT01659658) (ixazomib‐dexamethasone, n = 85; physician's choice of… read more here.
Keywords: ixazomib dexamethasone; physician choice; patients relapsed; quality life ... See more keywords
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4765
Abstract: Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy and safety profile of the… read more here.
Keywords: cell lymphoma; relapsed refractory; mantle cell; ibrutinib monotherapy ... See more keywords
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4820
Abstract: The autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell product, lisocabtagene maraleucel (liso‐cel), is administered at equal target doses of CD8+ and CD4+ CAR+ T cells. This analysis assessed safety and efficacy of liso‐cel in Japanese… read more here.
Keywords: cell; lisocabtagene maraleucel; liso cel; japanese patients ... See more keywords
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34756
Abstract: Teclistamab, a B‐cell maturation antigen × CD3 bispecific antibody, demonstrated an overall response rate of 63.0% in 165 heavily pretreated patients with relapsed or refractory multiple myeloma in the phase 1/2 MajesTEC‐1 study. Cytokine release… read more here.
Keywords: relapsed refractory; refractory multiple; patients relapsed; multiple myeloma ... See more keywords
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.577
Abstract: New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first‐in‐class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM. Identification… read more here.
Keywords: relapsed refractory; clinical implications; multiple myeloma; dose regimen ... See more keywords
OUTCOME OF PATIENTS WITH RELAPSED AND REFRACTORY PERIPHERAL T CELL LYMPHOMA INTENDED FOR STEM CELL TRANSPLANT
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_104
Abstract: OUTCOME OF PATIENTS WITH RELAPSED AND REFRACTORY PERIPHERAL T CELL LYMPHOMA INTENDED FOR STEM CELL TRANSPLANT S. Parkin* | S. Wong | J.M. Connors | L. Sehn | D. Villa | A. Gerrie | R.… read more here.
Keywords: relapsed refractory; refractory peripheral; outcome patients; patients relapsed ... See more keywords